Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076034" target="_blank" >RIV/65269705:_____/22:00076034 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/22:00129670

Result on the web

<a href="https://www.mdpi.com/2072-6694/14/10/2353" target="_blank" >https://www.mdpi.com/2072-6694/14/10/2353</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers14102353" target="_blank" >10.3390/cancers14102353</a>

Result language

angličtina

Original language name

Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Original language description

Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30200 - Clinical medicine

Project

<a href="/en/project/NU21-03-00306" target="_blank" >NU21-03-00306: Comprehensive genomic profiling in ovarian cancer patients treated with platinum-based chemotherapy: identification of predictive biomarkers and evaluation of the potential of precision oncology approach</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

10

Country of publishing house

CH - SWITZERLAND

Number of pages

13

Pages from-to

2353

UT code for WoS article

000803347900001

EID of the result in the Scopus database

2-s2.0-85129745472